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EBV causes B lymphomas and undifferentiated nasopharyngeal car-
cinoma (NPC). Although the mechanisms by which EBV infects B
lymphocytes have been extensively studied, investigation of the
mechanisms by which EBV infects nasopharyngeal epithelial cells
(NPECs) has only recently been enabled by the successful growth of
B lymphoma Mo-MLV insertion region 1 homolog (BMI1)-immortal-
ized NPECs in vitro and the discovery that neuropilin 1 expression
positively affects EBV glycoprotein B (gB)-mediated infection and
tyrosine kinase activations in enhancing EBV infection of BMI1-im-
mortalized NPECs. We have now found that even though EBV in-
fected NPECs grown as a monolayer at extremely low efficiency
(<3%), close to 30% of NPECs grown as sphere-like cells (SLCs) were
infected by EBV. We also identified nonmuscle myosin heavy chain
IIA (NMHC-IIA) as another NPEC protein important for efficient EBV
infection. EBV gH/gL specifically interacted with NMHC-IIA both
in vitro and in vivo. NMHC-IIA densely aggregated on the surface
of NPEC SLCs and colocalized with EBV. EBV infection of NPEC SLCs
was significantly reduced by NMHC-IIA siRNA knock-down. NMHC-
IIA antisera also efficiently blocked EBV infection. These data indicate
that NMHC-IIA is an important factor for EBV NPEC infection.
Epstein–Barr virus | nasopharyngeal carcinoma | NMHC-IIA | gH/gL | BMI1
EBV is a nearly ubiquitous human γ-herpesvirus that causesB-cell lymphomas and nasopharyngeal carcinoma (NPC),
indicative of tropism for both cell types (1–3). Until recently, the
molecular mechanisms of EBV infection of B lymphocytes were
better understood than the mechanisms of epithelial cell infection
(4). EBV attachment to the B-cell membrane is mediated by in-
teractions between EBV glycoprotein 350 (gp350) and comple-
ment receptor type 2 (CR2 or CD21) (5) or CD35 (6). EBV gp42
binding to HLA class II triggers EBV fusion with B cells in the
presence of EBV glycoprotein B (gB) and gH/gL (7, 8). For
epithelial cells, gH/gL and gB are important for EBV infection (4,
9, 10). Epithelial cells lack HLA class II expression; thus, gp42
cannot trigger EBV and cell fusion. Instead, gp42 inversely
suppresses the infection (11), and an antibody against gp350 can
enhance infections of CD21/CD35-negative epithelial cells (12).
The gH/gL heterodimer is required for virus entry (4) and may be
involved in binding (13), as well as fusion of EBV (14–17). How-
ever, the crystal structure of EBV gH/gL does not show any known
fusion domain (18). It is now thought that gH/gL regulates the
fusion function of gB (19). Binding of gH/gL to a subset of αv
integrins (e.g., αvβ5, αvβ6, or αvβ8) provides the initial trigger for
gB-mediated fusion (16, 20, 21). However, E1D1(gH/gL) antibody
or CL59(gH) antibody, with a different epitope, can impair epi-
thelial cell infection (20, 22). Thus, multiple gH/gL domains are
critical to EBV infection, and gH/gL may interact with proteins in
addition to integrins. Direct interaction of EBV gB amino acids
23–431 with neuropilin 1 (NRP1) and its associated tyrosine ki-
nases is critical for EBV infection of nasopharyngeal epithelial cells
(NPECs). NRP1 knock-down or EBV pretreatment with soluble
NRP1 suppresses EBV NPEC infection, whereas NRP1 over-
expression enhances EBV infection (10). Confocal microscopy and
experiments with inhibitors of macropinocytosis indicate that EBV
enters NPECs through macropinocytosis and not through clathrin-
mediated endocytosis (10).
The principal obstacle to identifying factors that may enable
more efficient EBV infection of NPECs and better understanding
of the role of EBV in NPC is that EBV is remarkably inefficient in
infection of primary or B lymphoma Mo-MLV insertion region 1
homolog (BMI1)-immortalized NPECs. As a polycomb complex
protein, BMI1 is a proto-oncogene. BMI1 has an important role
in regulating proliferation, senescence, and self-renewal of stem
cells (23, 24). BMI1 overexpression immortalizes human epithelial
cells and mouse embryonic fibroblasts (25, 26). By optimizing
the growth of BMI1-immortalized NPEC cultures, we found
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that BMI1-immortalized NPECs seeded at a 10-fold higher density
than used in previous protocols and grew initially as a monolayer.
“Spherical cells” then grew above the monolayer. Surprisingly,
the spherical cells consistently supported an EBV infection effi-
ciency of ∼20–30%, using an estimated EBV multiplicity of in-
fection (MOI) of 300. Using this more efficient in vitro EBV
infection protocol, we identified an interaction between nonmuscle
myosin heavy chain IIA (NMHC-IIA) and gH/gL on the cell sur-
face, which was critical for more efficient EBV NPEC infection.
Results
Establishment of an Efficient in Vitro EBV Infection Model for
BMI1-Immortalized NPECs. We screened primary NPECs, BMI1-
immortalized NPECs, and NPC cell lines for susceptibility to
cell-free EBV infection. Consistent with previous reports, rela-
tively higher infection efficiencies could only be achieved using
very high EBV MOIs: i.e., ∼2,500–10,000 per cell (10). BMI1-
immortalized NPECs seeded at higher densities than previously
formed dense monolayers with sphere-like cells (SLCs) growing
above the confluent NPEC monolayer cells (MLCs) (Fig. 1A,
white arrowheads). Most importantly, SLCs were much more
efficiently infected by cell-free recombinant EBV expressing
eGFP (EBV-eGFP) at an MOI of ∼300, whereas MLCs under
usual culture conditions were sparsely infected (Fig. 1A). SLCs
made by seeding 5 × 105 NPEC/BMI1 cells in 48 wells for 36 h
were ∼10-fold more highly infected than under previous culture
conditions. In subsequent experiments, SLCs formed routinely
by seeding 5 × 105 NPEC/BMI1 cells in 48-well plates. The in-
fection efficiency of SLCs from NPEC1-BMI1 or NPEC2-BMI1
cells reached 28.4% and 28.0%, respectively, whereas eGFP-
positive cells were only 1.4% and 2.6% in monolayer cultured
NPEC1-BMI1 and NPEC2-BMI1 cells at an MOI of about 300
(Fig. 1B). The low infection efficiency of monolayer cultured cells
by cell-free EBV is similar to a previous report (9). Moreover, the
mean fluorescence intensities (MFIs) of EBV-infected SLCs from
NPEC1-BMI1 and NPEC2-BMI1 cells were increased by ∼39-fold
and ∼28-fold relative to MLCs (Fig. 1B).
To determine if CD21 and CD35 are involved in NPEC/BMI1
EBV infection, we evaluated CD21 and CD35 mRNA expression
by quantitative RT-PCR (qRT-PCR) and found none in SLCs (Fig.
S1A). Thus, high SLC infection rates were not mediated by CD21
or CD35. To screen for other glycoproteins that might mediate SLC
infection, we used an antibody-blocking assay, which showed that
antibodies against gH/gL (CL59) or gH (E1D1) efficiently blocked
SLC EBV infection, whereas 72A1 antibody to gp350 enhanced
epithelial cell infection (Fig. 1C and Fig. S1 B and C). These results
are consistent with previous observations (12, 13) indicating that
EBV gH and gL are critical for EBV NPEC infection.
NMHC-IIA Interacts with gH/gL.To identify gH/gL interacting proteins
other than integrins, a myc-tagged gH/gL pull-down was subjected
to liquid chromatography-tandem MS (MS/MS) proteomic analy-
sis. EBV-infected SLC lysates were immunoprecipitated with myc-
tagged gH/gL. A protein of ∼250 kDa (Fig. 2A) was pulled down
and identified by liquid chromatography-MS/MS as NMHC-IIA
(Fig. 2B). To verify the association of EBV gH/gL with NMHC-
IIA, co-immune precipitation assays were done in HEK 293T cells
transfected with FLAG-tagged gH/gL or control plasmids. Immune
precipitation with an anti-FLAG antibody identified an association
of gH/gL with endogenous NMHC-IIA in HEK 293T cells, whereas
a control did not associate with NMHC-IIA (Fig. 2C). Further, GST
pull-down assays revealed that a NMHC-IIA C-terminal amino acid
1,665–1,960 GST fusion protein bound directly to purified myc-
tagged gH/gL (Fig. 2D), whereas GST alone did not. These data
indicate that gH/gL interacts with NMHC-IIA in vivo and in vitro.
NMHC-IIA Is Located on SLC Membranes and Interacts with gH/gL.
NMHC-IIA mainly localized to the cell cytoplasm. HSV-1 infection
redistributes NMHC-IIA to the cell membrane (27). We examined
NMHC-IIA distribution in MLC and SLC cytoplasmic or cell
membrane fractions. NMHC-IIA was mostly in the MLC cyto-
plasmic fraction, and only a minimum amount was in the mem-
brane fraction (Fig. 3A), consistent with previous reports (28). In
contrast, NMHC-IIA protein was very abundant in SLC membrane
fractions (Fig. 3A). To further examine whether gH/gL was asso-
ciated with NMHC-IIA in the membrane fraction, myc-tagged
gH/gL was immunoprecipitated from SLC or MLC membrane
fractions and blotted for NMHC-IIA. Myc-tagged gH/gL brought
down NMHC-IIA from SLC membrane fractions but not from
MLC membrane fractions (Fig. 3B). Immunofluorescent staining
found NMHC-IIA aggregated on the SLC surface, whereas only
weak staining was observed on the neighboring MLC surface.
In Triton X-100–treated cells, NMHC-IIA was very abundant
in the cytoplasm of MLCs surrounding the SLCs (Fig. 3C). We
also evaluated the colocalization of EBV and NMHC-IIA on SLC
Fig. 1. High-efficiency EBV infection using BMI1-immortalized NPECs. (A) NPEC1
or NPEC2 BMI1 cells were seeded at 5 × 104 or 5 × 105 into 48 well plates for
36 h. Cells at 5 × 104 density grew as confluent MLCs, whereas cells at 5 × 105
density formed two layers, with SLCs (white arrowheads indicated) above MLCs.
SLCs were more susceptible to EBV infection, whereas MLCs were more resistant
to infection. EGFP-positive cells were indicative of successful infection. (B) Per-
centages and MFIs of infected MLCs and SLCs after exposure to EBV-eGFP were
analyzed by flow cytometry. The percentages and MFIs of the infected cells
were quantified and are labeled above the histogram graph. Gray lines show
mock infection, and black lines show EBV-eGFP infection. (C) SLCs originated
from NPEC1 or NPEC2 BMI1 cells and were exposed to EBV-eGFP after pre-
treatment with 100 μg/mL mouse IgG, 72A1 (antibody to gp350), E1D1 (anti-
body to gH/gL), and CL59 (antibody to gH) at 4 °C for 1 h. The infected cell MFIs
were measured by flow cytometry 24 h after infection. The mean value of the
control IgG was normalized to 100% relative MFI. The error bars are ±SEM.









membrane. After coculture of EBV and SLCs, antibodies against
gp350 and NMHC-IIA were used to visualize EBV and NMHC-
IIA using confocal microscopy. We found extensive colocalization
of gp350 and NMHC-IIA in NPEC1-BMI1 SLC membranes (Fig.
3D). These results indicate that SLC formation caused NMHC-
IIA to localize to the cell membrane, and thereby increased EBV
SLC infection.
Endogenous NMHC-IIA Inhibition Reduces EBV Binding and SLC
Infection. To evaluate the role of endogenous NMHC-IIA in EBV
infection of NPEC/BMI1 cells, siRNA knock-down and blocking
assays were done. Two siRNAs that target NMHC-IIA were used
to reduce NMHC-IIA mRNA and protein expression in NPEC/
BMI1 SLCs (Fig. 4A and Fig. S2A). The siRNAs targeting NMHC-
IIA significantly reduced SLC NMHC-IIA expression compared
with a negative control siRNA. Decreased membrane NMHC-IIA
expression was also evident by immunofluorescence staining in the
absence of permeabilization (Fig. S2 B and C). NPEC/BMI1 SLCs
with reduced NMHC-IIA were then infected with EBV-eGFP.
Flow cytometry was used to evaluate eGFP expression following
EBV infection. NMHC-IIA siRNA knock-down in NPEC1-BMI1
and NPEC2-BMI1 SLCs significantly reduced eGFP signals
compared with control siRNA treatment (Fig. 4B). Furthermore
NMHC-IIA knock-down did not affect adenovirus infection (Fig.
4B), consistent with an EBV-specific effect. qRT-PCR was also
used to quantify EBVDNA after EBV infection of NPEC1-BMI1
SLCs with reduced NMHC-IIA expression. EBV was incubated
with NPEC/BMI1 SLCs expressing reduced NMHC-IIA at 4 °C
for 2 h. NMHC-IIA siRNA knock-down significantly (60–82%)
reduced EBV copy number compared with control siRNA knock-
down (Fig. 4C). An antibody-blocking assay was used to further
confirm the role of NMHC-IIA in EBV infection. Preincubation
of SLCs with a polyclonal NMHC-IIA antibody at 30, 60, or 150
μg/mL inhibited EBV infection in a dose-dependent manner. An-
tibody blockage at 150 μg/mL reduced MFI by 63% and 72% in
NPEC1-BMI1– and NPEC2-BMI1–originated SLCs, respectively
(Fig. 4D). In contrast, the NMHC-IIA antibody had no effect on
adenovirus infection (Fig. 4D). Collectively, these results indicate
that endogenous NMHC-IIA has a significant role in EBV in-
fection of NPECs.
Expression of NMHC-IIA in Dysplastic Epithelial Cell Membranes. We
also evaluated NMHC-IIA expression in normal and dysplastic
epithelial cells by immune histochemistry (IHC). NMHC-IIA was
highly expressed in the cytoplasm and cell membrane in two of
three Epstein–Barr virus-encoded small RNAs (EBERs)-positive
dysplastic epithelial tissues (Fig. S3 A andC). However, NMHC-IIA
expression was low in all 12 normal epithelium controls (Fig. S3B),
and EBERs were not detected in normal epithelium (Fig. S3D).
Discussion
This study describes an improved and more efficient NPEC EBV
infection model. Using this model, NMHC-IIA was identified as
an EBV gH/gL interactive cell protein that has an important role
in mediating NPEC EBV infection. Previous studies highlighted
two other methods that improved the efficacy of EBV epithelial
infection: B-cell transfer infection and cell-free EBV infection.
B-cell transfer is a process in which a B cell producing EBV, or
Fig. 2. NMHC-IIA interacts with gH/gL. (A) Precipitation of the SLC lysates with myc-gH/gL (lane 1) and BSA (lane 2). The precipitates were separated by SDS/PAGE
and subjected to silver staining, and myc-gH/gL was used as a control to exclude false-positive bands. The black arrows indicate the gH/gL, IgG heavy chain (HC),
IgG light chain (LC), and a protein differentially pulled down by gH/gL above 170 kDa. (B) Sequence coverage (red) for the NMHC-IIA from liquid chromatography-
MS analyses of the excised differential band in A. (C) Lysates of 293T cells transfected with pcep2 vector, pcep2-FLAG-gH/gL, were precipitated with FLAG-M2-
antibody and FLAG-gH/gL, and endogenous NMHC-IIA was blotted with FLAG-M2 and NMHC-IIA antibodies, respectively. IB, immunoblot. (D) Equivalent amounts
of soluble GST and GST-NMHC-IIA-C (amino acids 1,665–1,960) proteins were precipitated with the purified soluble myc-gH/gL. The precipitates were blotted with
a myc-antibody. Coomassie blue staining showed equivalent input protein levels in each assay.
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having EBV bound to its surface, transfers EBV to an epithelial
cell receptor (9, 29–31). Various epithelial cell lines have been
evaluated for direct EBV infection. However, EBV transfer in-
fection was not efficient at low MOIs (31). An improvement in
EBV infection efficiency was obtained by ectopically expressing
CD21 in epithelial cells (32). In the absence of increased CD21 or
CD35 expression, we consistently found that EBV infection effi-
ciencies could reach 10–20% when NPEC1-BMI1 cell lines were
Fig. 3. NMHC-IIA located on the SLC membrane. (A) Membrane or its associated MLC and SLC proteins were cross-linked with 3,3′-dithiobis(sulfosuccinimidyl
propionate) (DTSSP) and extracted with the ProteoExtract Native Membrane Protein Extraction Kit. The presence of α-tubulin and E-cadherin indicated the
cytoplasm and membrane fractions, respectively. The presence of NMHC-IIA was measured in the MLC and SLC cytoplasm and membrane fractions. cyto,
cytoplasm fraction; mem, membrane fraction. (B) MLC and SLC membrane proteins were immunoprecipitated with purified myc-gH/gL, and the immuno-
precipitates (IP) were blotted with NMHC-IIA and myc tag antibodies. (C) Typical 3D immunostaining image of NMHC-IIA localization in a field after SLC
formation. The cells were incubated with the NMHC-IIA antibody or control IgG, followed by an AF488-conjugated secondary antibody with or without
permeabilization by 0.1% Triton X-100 (TriX100) treatment. The nuclei were stained with DAPI (blue). (D) Typical 3D immunostaining image of a sphere
surface for visualizing the colonization of EBV and NMHC-IIA. NPEC1-BMI1 SLCs were exposed to cell-free EBV-eGFP at 4 °C for 2 h. Then, the unbound EBV
was removed by washing with prechilled PBS three times. EBV and NMHC-IIA on the surface of the SLCs were stained with 72A1 (green) and NMHC-IIA (red)
antibodies without permeabilization. The nuclei were stained with DAPI (blue). b, blue, g, green, r, red.
Fig. 4. Inhibition of endogenous NMHC-IIA reduced EBV infection of the SLCs. (A) Protein expression levels of NMHC-IIA were determined by immuno-
blotting 48 h after siRNA transfection. (B) Twenty-four hours after transfection, the siRNA-treated cells were reseeded into 48 well plates to form the SLCs.
The SLCs were exposed to EBV-eGFP or AdV-eGFP at an MOI of 300 and 10, respectively. Then, the infected cell MFIs were determined 24 h postinfection by
flow cytometry. The data are shown as mean and SEM (n = 3; two-tailed Student’s t test). The mean value of the negative control (NC)-treated SLCs was
normalized to 100% relative MFI. The error bars are ±SEM. *P < 0.05; **P < 0.01. (C) EBV copy number on the NMHC-IIA siRNA-treated SLCs was detected with
a Taqman probe-based qRT-PCR method. **P < 0.01; ***P < 0.001. (D) MLCs and SLCs of the BMI1-immortalized NPECs were pretreated with the indicated
concentrations of polyclonal NMHC-IIA antibody or IgG for 1 h at 4 °C. Then, they were exposed to EBV-eGFP or AdV-eGFP at an MOI of 300 and 10, re-
spectively. The infected cell MFIs were determined 24 h after infection by flow cytometry. The data are shown as mean and SEM (n = 3). The mean value in the
presence of the indicated IgG concentration was normalized to 100% relative MFI. The data are shown as mean and SEM (n = 3; two-tailed Student’s t test).
The error bars are ±SEM. ns, not significant. *P < 0.05; **P < 0.01.









exposed to high MOIs, such as 2,500–10,000 (10). We have now
found that non–CD21-converted, BMI1-immortalized NPEC epi-
thelial cells can be infected with cell-free EBV at a high efficiency
and with a relatively low EBVMOI of 300 per cell. Although EBV
has not been readily detected in normal nasopharyngeal epithelia,
EBV is readily detected in dysplastic nasopharyngeal epithelia and
poorly differentiated NPC cells (33). Primary nasopharyngeal epi-
thelial infection may occur in epithelial cells at different stages
of development. In precancerous stages, normal nasopharyn-
geal epithelia, composed of simple columnar or pseudostratified
columnar epithelial cells, become disrupted or dysplastic (33)
(Fig. S3). Stratified epithelia have been readily infected in an
in vitro model (34). BMI1-immortalized NPECs used in these
studies had high telomerase activity and reduced p16 expression
(25, 26), which are common molecular changes in precancerous
nasopharyngeal epithelia (33, 35). SLCs formed from BMI1-
immortalized cells may be a model for dysplastic epithelia or
precancerous lesions.
EBV gH/gL heterodimers have been reported to bind (13) and
fuse (14, 15, 20) to epithelial cells. Integrins α5β1, αvβ5, αvβ6, and
αvβ8 are important for EBV infection of epithelial cells (9, 16, 20).
Interactions of gH/gL with integrins may trigger virus envelope and
cell membrane fusions (16). We have now found that NMHC-IIA
is also important for EBV infection of epithelial cells. Although
NMHC-IIA is mainly located in the cell cytoplasm, it is also an
HSV-1 entry receptor that can be recruited to membranes when
HSV-1 attaches to a cell (27). EBV and HSV-1 are evolutionarily
related, but also divergent, human herpes viruses that appear to
use similar strategies to infect target cells. We found that aggre-
gated NMHC-IIA in apical surfaces of SLCs and NMHC-IIA–
enriched membranes likely contribute to high EBV SLC infection
efficiency.
NMHC-IIA is highly expressed in the cytoplasm and in dys-
plastic epithelial cell membranes by IHC staining (Fig. S3A).
NMHC-IIA expression correlated with EBV infection of dysplastic
epithelium, as detected by EBER probes (Fig. S3C). NMHC-IIA
was expressed at relatively low levels (Fig. S3B), however, and
EBERs were not detected in normal epithelium (Fig. S3D). Be-
cause EBV infection did not alter NMHC-IIA expression (Fig. S4),
our finding indicates that cells with high levels of NMHC-IIA are
more permissive to EBV infection.
NMHC-IIA overexpression in the cytoplasm, without an increase
in membrane fraction, did not promote higher EBV infection.
Similarly, constitutively high cytoplasmic NMHC-IIA expression
had limited effects on EBV infection efficiencies. Higher EBV in-
fection only occurs when NMHC-IIA is redistributed to the cell
membrane. The mechanisms through which NMHC-IIA is redis-
tributed to the cell membrane are still not clear. Our data are
consistent with a model in which EBV gH/gL interactions with
NMHC-IIA and integrins promote efficient EBV entry to epithe-
lial cells. EBV gB and NRP1 are also important for efficient epi-
thelial cell infection (10, 19), where NRP1 facilitates internalization
and fusion, as well as macropinocytosis and lipid raft-dependent
endocytosis, via direct protein–protein interaction.
The discovery that EBV exploits NMHC-IIA and NRP1 for
entry into epithelial cells has important implications for the de-
velopment of NPC. Inhibitors that can interrupt NMHC-IIA; NRP1;
integrins; and EBV gH/gL, gB, or BMRF2 interactions may prevent
EBV entry or transformation of NPECs to NPC.
Materials and Methods
Cells, Virus, and Reagents. Primary NPECs and BMI1-immortalized NPECs were
grown in keratinocyte serum-free medium (17005-075; Invitrogen). HEK 293T
and CHO cells were maintained in DMEM supplemented with 10% (vol/vol)
FBS. Akata (EBV-eGFP) and hybridoma cells were grown in RPMI medium
1640 supplemented with 5% (vol/vol) or 10% (vol/vol) FBS, respectively, in
humidified 5% (vol/vol) CO2 incubators at 37 °C. EBV-eGFP cells were made as
previously described (36, 37). Briefly, EBV-eGFP cells were produced from Akata
(EBV-eGFP) cells by cross-linking cell surface IgG proteins using 0.8% goat anti-
human IgG. MLCs and SLCs were exposed to cell-free EBV-eGFP at an MOI of
300 in buffered serum-free RPMI 1640 for 3 h at 37 °C, and excess virus was
removed by washing three times with PBS. Antibodies included monoclonal
antibodies CL59 to gH (13, 38), E1D1 to gHgL (39), and 72A1 to gp350, obtained
from hybridoma (HBM168; American Type Culture Collection) cells. Rabbit IgG
was purchased from R&D Systems. Antibody to NMHC-IIA (ab24762) was pur-
chased from Abcam. Rabbit polyclonal antibodies to NMHC-IIA were used to
block EBV infection and were produced by immunization with NMHC-IIA
(amino acids 1,665–1,960) obtained from Proteintech, with a nonimmunized
rabbit IgG used as a control.
Formation of SLCs. A total of 5 × 105 and 5 × 106 BMI1-immortalized NPECs
were seeded into 48 well plates and six well plates, respectively. The medium
was changed twice daily with preheated keratinocyte serum-free medium to
avoid starvation. SLCs formed within 36 h on MLCs.
Determination of Virus Copy Number. To determine the EBV copy number, a
TaqMan probe-based qRT-PCR assay was conducted to detect the BamHI-W
fragment of the EBV genome (40). A calibration curve was made by detecting
the BamHI-W DNA fragment following extraction from Namalwa cells, which
contained two integrated viral genomes per cell. The EBV copy number can be
calculated in the calibration curve. The estimated MOI of EBV infection is de-
termined by real-time PCR for EBV DNA copy number.
Myc-gH/gL Pull-Down, GST Pull-Down, and Co-Immunoprecipitation Assays. For
theMyc-gHgL pull-down assay, lysates from 5 × 107 SLCs were incubated with
9E10 cross-linked agarose beads and 10 μg of myc-gH/gL or 10 μg of BSA in a
TNE buffer [50 mM Tris·HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40,
0.5 mM EDTA, and Roche proteinase inhibitor mixture] for 4 h. The agarose
beads were collected following centrifugation and washed four times with
TNE buffer. Then, a SDS-buffer solution was added to the agarose beads,
and the solution was boiled at 98 °C for 5 min. Next, the proteins that pulled
down were separated by SDS/PAGE and subjected to silver staining (P0017S;
Beyotime). The soluble myc-gH/gL, myc-tagged gH (amino acids 18–679, lack
of intracellular and transmembrane domain), and myc-tagged gL (amino
acids 24–137) proteins were expressed and purified in an adenovirus ex-
pression system (SI Materials and Methods). For co-immunoprecipitation,
293T cells were transfected with pcep2-vector, pcep2-FLAG-gH (amino acids
18–679), or pcep-FLAG-gL (amino acids 24–137). Thirty-six hours later, the
cells were lysed in TNE buffer and centrifuged for 10 min at 15,294 × g.
The supernatants were incubated with FLAG-M2-Beads (Sigma) for 2 h at
4 °C. The immunoprecipitates were collected, washed, and analyzed by immu-
noblotting with NMHC-IIA antibody. For GST pull-downs, glutathione-Sepharose
beads that contained equivalent GST or GST-NMHC-IIA-C [GST-NMHC-IIA (amino
acids 1,665–1,960)] levels, which were expressed and purified in Escherichia coli
BL21 cells (SI Materials and Methods), were incubated with myc-gH/gL in TNE
buffer overnight at 4 °C. Beads were collected, washed, and analyzed by im-
munoblotting with a myc antibody.
Membrane Protein Extraction. A total of 5 × 106 BMI1-immortalized NPECs
were seeded into six well plates, and 36 h later, the membrane proteins
were cross-linked with 3,3′-dithiobis(sulfosuccinimidyl propionate) (DTSSP)
(21578; Pierce) at a final concentration of 2 mM in buffered PBS for 2 h on
ice. The assay was stopped in 50 mM Tris buffer (pH 7.5) after 15 min. After
cross-linking of membrane proteins, SLCs were separated from the MLCs
with a time-controlled 0.02% EDTA/PBS treatment and pipetted without
destroying the MLCs. The cytoplasm and membrane fractions of the sepa-
rated SLCs and MLCs were extracted in six well plates according to the
ProteoExtract Native Membrane Protein Extraction Kit (catalog no. 444810;
Calbiochem) instructions. The extracted cytoplasm and membrane protein
concentrations were measured using a QuantiPro BCA Assay Kit (Sigma).
Equivalent amounts of MLC and SLC protein were incubated with myc-gH/gL.
Immune precipitates were blotted with NMHC-IIA antibody.
Knock-Down Assays. The siRNAs that targeted NMHC-IIA were obtained from
Guangzhou RiboBio Co., Ltd., and a total of 2.75 × 105 BMI1-immortalized
NPECs were seeded into six well plates. When cell densities reached 80%,
cells were transfected with siRNAs using RNAi MAX transfection reagents
(Invitrogen), according to the manufacturer’s instructions. Twenty-four hours
later, 5 × 105 cells were reseeded into 48 well plates to form the SLCs and were
subjected to EBV infection after 36 h. The infected cell MFIs were measured by
flow cytometry within 24 h postinfection.
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Virus Binding Assays. Virus binding assay used a previously published protocol
(32). Briefly, virus bound to the cells was harvested after the virus was in-
cubated with cells for 2 h at 4 °C. Then, cells were washed three times with
PBS and supplemented with protease inhibitors (Roche) and 15 mg/mL BSA.
EBV DNA was isolated using a Blood DNA Kit (Omega), and the relative virus
copy number was determined by qRT-PCR (40).
Antibody-Blocking Assay. For antibody-blocking assays, SLCs were pretreated
with a polyclonal NMHC-IIA antibody, which was serially diluted to con-
centrations of 150, 60, and 30 μg/mL in RPMI 1640, or with 150 μg/mL control
IgG for 1 h at 4 °C. Cells were then infected with EBV without removing
antibody for 3 h at 37 °C. The MFIs of the infected cells were measured
within 24 h postinfection by flow cytometry.
FACS Analysis. To detect the percentages and MFIs of EBV-infected cells, cells
were trypsinized to a single-cell suspension within 24 h postinfection and
were evaluated by flow cytometry (FACS Diva Option; Becton Dickinson).
Immunostaining and Confocal Microscopy. Immunostaining was done using a
previously described method (41). Briefly, NMHC-IIA expression levels on MLCs
or SLCs were evaluated by indirect immunofluorescence of cells sequentially
incubated with a polyclonal rabbit NMHC-IIA antibody (ab24762; Abcam) and
AF488/AF594-conjugated anti-rabbit IgG (Life Technology). EBV and NMHC-IIA
levels were evaluated using the 72A1 and NMHC-IIA antibodies, respectively,
followed by a combined incubation of anti-mouse IgG and anti-rabbit IgG; they
were then conjugated with AF488 and AF594, respectively. After washing three
times for 5 min, slides were stained with 0.5 μg/mL DAPI (Sigma) to visualize the
nuclei and were examined using anOlympus confocal imaging system (Olympus
FV1000) with an oil immersion objective with a magnification of 40×. Images
were analyzed via Olympus FV 1000 software (Fluoview, version 1.7; Olympus).
Each experiment was done in triplicate.
Statistical Analysis. Statistical analyses were performed using the statistical
software package SPSS13.0 (IBM). The significance of treatments was de-
termined using the Student’s t test. P values ≤0.05 were considered to be
statistically significant.
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